Kaleido Biosciences

21 articles with Kaleido Biosciences

• 

  BioSpace Movers & Shakers, Nov. 8

  11/8/2019

  Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments.

• Kaleido Biosciences Appoints William Duke as Chief Financial Officer

  11/6/2019

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced the appointment of William Duke as Chief Financial Officer (CFO), effective November 25, 2019

• Kaleido Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

  10/30/2019

  Kaleido Biosciences, Inc., a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, announced financial results for the third quarter ended September 30, 2019, and provided a corporate update.

• Kaleido Biosciences and Washington University School of Medicine to Collaborate on Exploring the Influence of Microbiome Metabolic Therapies (MMT™) on Physiology and Metabolism

  10/22/2019

  Kaleido Biosciences, Inc. has entered into a research collaboration with Jeffrey Gordon, M.D., Director of the Edison Family Center for Genome Sciences and Systems Biology at Washington University School of Medicine, to explore the influence of Microbiome Metabolic Therapies on microbial and host physiology and metabolism.

• 

  Clinical Catch-Up: September 2-8

  9/9/2019

  Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
• 

  BioSpace's List of February 2019 Life Science IPOs

  2/28/2019

  A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
• 

  BioSpace's List of January 2019 Life Science IPOs

  1/31/2019

  A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
• 

  Despite Government Shutdown, Kaleido and Cirius File for IPOs

  1/14/2019

  Despite the government shutdown, at least two biotech companies, Kaleido Biosciences and Cirius Therapeutics, have filed with the U.S. Securities and Exchange Commission (SEC) for initial public offerings (IPO).

• Kaleido Biosciences Announces Appointment of New Members to its Board of Directors

  12/20/2018

  Kaleido Biosciences, a healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the appointment of three new members to its Board of Directors:

• Kaleido Biosciences Announces Appointment of Katharine Knobil, M.D., as Chief Medical Officer and Head of Research & Development

  12/3/2018

  Dr. Knobil joins Kaleido from GlaxoSmithKline (GSK), where she most recently served as CMO

• 

  Biotech IPOs Are Booming … but for How Long?

  9/19/2018

  According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
• 

  A Deep Dive into This Year’s Biotech IPOs

  7/24/2018

  So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.

• Kaleido Biosciences Raises $101 Million Series C Financing

  6/25/2018

  Oversubscribed Financing Includes New and Existing Investors

• Kaleido Biosciences Announces Appointment of Joshua Brumm as Chief Financial Officer

  4/23/2018

  Kaleido Biosciences, a clinical-stage biotechnology company developing novel chemistries to unlock the power of the human microbiome, today announced the appointment of Joshua Brumm as chief financial officer.

• Kaleido Biosciences Announces Appointments to Leadership Team

  3/26/2018

  Stephen Sofen, Ph.D. to head technical operations and Susan Stewart, J.D. to lead regulatory affairs and quality

• Kaleido Biosciences Announces Appointment of Wendy Arnold as Senior Vice President, Human Resources

  1/3/2018

  Ms. Arnold, who brings more than 20 years of experience in human resources to Kaleido, will report directly to chief executive officer and chair, Michael Bonney.

• Kaleido Biosciences Expands Leadership Team with Appointment of Alison Lawton as President and Chief Operating Officer

  12/12/2017

  Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry.

• Kaleido Biosciences Adds Two Senior Leaders to Guide Next Phase of Growth

  11/2/2017

  Kaleido Biosciences announced today the appointment of John W. Davies, Ph.D. as chief technology officer and Michael D. Bruce, Ph.D. as senior vice president, project, portfolio and alliance management.

• Kaleido Biosciences And CoreBiome Partner To Accelerate Microbiome Therapeutic Development

  10/10/2017

• BioPharm Executive: Money Talk

  9/27/2017

  Venture capital is hopping, attracted to some of the past several years' successes.